The playbook behind
IM8's billion.

Bottom line up front: the lazy read on IM8 is "celebrity brand goes viral." The data says otherwise. Celebrity launches fail constantly, and none of them produce cohort curves a billion-dollar fund will underwrite. IM8 earned this deal by building subscription-grade unit economics into a consumer product from day one, and that part, unlike the Beckham part, is something other brands can actually copy.

I broke down the financing structure itself in the non-dilutive CAC financing explainer. This post is the other half of the story: the growth data that earned the check, the strategy behind the numbers, the bear case, and the operator playbook that falls out of it.

The number that
earned the billion.

Here it is: per Prenetics, every dollar IM8 has ever spent acquiring a customer has already returned $1.44 in gross profit, and the figure keeps rising because those customers are subscribers (Prenetics, July 2026). That single number, more than the Beckham name, is why General Catalyst wrote a billion-dollar commitment without taking a share of the company.

Quick recap of the structure, since it shapes everything below. General Catalyst's Customer Value Fund finances up to 70% of IM8's monthly marketing spend and gets repaid from a capped share of the revenue generated by the exact customers that spend acquires (TechCrunch, July 2026). No equity, no board seat, no maturity date, and no recourse beyond the funded cohorts. If a cohort underperforms, that loss belongs to the fund.

Investor David Lasday put the sharpest frame on it in his read on the deal: General Catalyst isn't betting on Beckham's name recognition. It's betting on a repeatable, already-validated acquisition engine, and structuring the entire deal so its return is tied to that engine's performance rather than the brand's equity value. A billion dollars where the investor only gets paid if the acquisition actually works is a very different kind of conviction than a growth round.

It's also only the second time the fund has deployed a check this size, after Grammarly's $1 billion in May 2025 (TechCrunch, May 2025). Grammarly is software. IM8 is a physical consumer product with shipping costs and churn. That makes this the most aggressive test yet of the "marketing as capex" thesis on a brand that ships boxes.

The fastest ramp the
category has seen.

IM8 launched in December 2024 and reached roughly $200 million in implied annualized revenue by May 2026, about 19 months later (Prenetics Q1 2026 results). For context, the best-known names in supplements took years, not months, to cross $100 million. Whatever you think of the product, the ramp is close to unprecedented for the category.

The shape of the revenue matters as much as the size. Customers sit in 43 countries, with over 60% of revenue coming from outside the US. The operation delivers roughly 200,000 servings a day, an order about every 27 seconds (Prenetics, June 2026). All the figures in this post are company-reported, so weigh them accordingly, but Prenetics is a Nasdaq-listed company publishing audited annual numbers, not a private brand quoting its own dashboard.

What General Catalyst
actually underwrote.

General Catalyst didn't underwrite revenue, it underwrote predictability. Its Adit Swarup said IM8's "underlying cohort economics are among the strongest we've seen," with retention "highly consistent across geographies, subscription tenors, and product" lines (Prenetics, July 2026). A fund that gets repaid from cohort revenue cares about one thing: whether the cohort curves hold. IM8 had 18 months of unusually clean ones to show.

Two trends in that table did the heavy lifting. The first is that payback got faster while the brand scaled. Most brands watch CAC payback stretch as they grow, because the marginal customer costs more than the early adopter. IM8's went the other way, from 3.9 months to 3.5. If you want to know where your own vertical sits, I keep CAC payback benchmarks by vertical for exactly this comparison.

The second is the quarterly billing shift, and I'd call it the single most consequential move in the whole dataset. In Q1 2026, IM8 deliberately pushed new customers from monthly to quarterly plans. Half of Beckham Stack customers and over a third of Essentials Pro customers took them. New-customer AOV jumped from $157 to $240, up 53% in one quarter (Prenetics, June 2026).

Why does that matter so much? Quarterly billing pulls three months of cash forward, which mechanically shortens payback, improves day-one CAC recovery, and cuts fulfillment frequency. It also cuts cancellation decisions from twelve a year to four. And, not coincidentally, it makes the cohort cash flows that repay General Catalyst faster and more predictable. My read: the quarterly-plan push was deal preparation. IM8 was engineering the exact curves a cohort financier wants to see.

Five choices that
built the numbers.

Strip out the headline and IM8's model comes down to five deliberate decisions. None of them require a footballer.

1. Celebrity as co-founder, not endorser

Beckham is a co-founder with equity, not a paid face. The origin story, his frustration with taking a fistful of pills every morning, is a product story rather than an ad campaign. The same alignment runs down the ambassador stack: Jay Shetty and Giannis Antetokounmpo are described as equity partners, not campaign hires. Equity buys duration. A partner whose payoff is the brand's terminal value promotes for years, and audiences can tell the difference. This is the same shift I traced in how celebrity DTC brands now exit: talent has moved from campaign fees to cap tables.

2. A credibility stack built for a low-trust category

Supplements are an unregulated, low-trust category, and IM8 treated that as the opening. A scientific advisory board with real names, every batch third-party tested against 280 banned substances, and clinical trials registered on ClinicalTrials.gov. The batch testing is what makes professional athletes safe to sign, which in turn makes the athlete partnerships credible. One honest footnote: an independent review of the trials found them small and designed to flatter, with results posted late (Dollar Commerce, 2026). The credibility stack is real as marketing infrastructure. As science, it's thinner than the branding implies, and scrutiny always arrives eventually.

3. DTC-only, subscription-first, on purpose

IM8 skipped retail entirely. At a roughly $100 price point, a shelf can't explain the product; a landing page, a Beckham video, and an advisory-board masterclass can. The quieter reason matters more: DTC keeps first-party cohort data clean, and you cannot underwrite reference-income financing on wholesale revenue. The ~80% new-customer subscription rate is the load-bearing number in the entire model. Under half and you have a repeat-purchase brand, not an annuity, and annuities are what get financed.

4. Premiumize instead of discounting

Most brands buy growth with discounts and watch AOV and margin erode. IM8 scaled up-market while growing: bundles like the Beckham Stack, a second premium longevity SKU, and the quarterly plans. Blended AOV went from about $110 in FY 2025 to $133 in Q4 to $159 in Q1 2026, with new-customer AOV at $240. That's why payback shortened while the brand scaled instead of stretching. The margin you protect is the margin a financier will later price against.

5. Global from day one

Most US brands treat international as a year-five project. IM8 treated the Beckham brand as a global asset from launch, and he's arguably more famous in the UK, Asia, and Latin America than in the US. The result is 43 countries and over 60% of revenue outside the US, which did double duty: it diversified demand and it made the cohort data more fundable, because General Catalyst explicitly cited retention consistency across geographies as an underwriting factor.

The bear case is
worth taking seriously.

The operator discourse around this deal has been better than the press coverage. Curtis Howland's breakdown of the rev-share structure and the comment threads under it and Lasday's post read like a decent risk register. Four concerns stand out, and none of them are dumb.

The structural skeptics deserve a line too. The sharpest comment under Lasday's post called the deal "the world's largest merchant cash advance," and on the mechanics that critique isn't wrong: money in now, repaid from future revenue. The differences are the cap, the cohort matching, and the non-recourse downside, which no merchant cash advance offers. Another commenter pushed on the headline number itself, noting $1.44 of gross profit per acquisition dollar is unremarkable if it's a short-window figure. Fair. It's a cumulative, to-date number that blends week-old cohorts with mature ones, so it understates where mature cohorts land, but it also isn't the 3x LTV to CAC some coverage implied. Treat it as directional.

And churn is the quiet variable underneath all of it. Subscription supplement brands live and die on the retention curve after month six, which is exactly what I cover in the DTC subscription churn breakdown. If IM8's curves hold, this deal looks brilliant in two years. If they don't, the fund wears the first loss and the model takes the reputational hit.

The playbook: become
underwritable.

Forget "get a celebrity" and forget "raise a billion." The meta-lesson is that cohort predictability has become a fundable asset, and the profile that got IM8 its terms exists at every scale, from Shopify Capital and Clearco up through CVF-style CAC financing. Building toward that profile is a strategy in itself. Six moves, in order of impact:

1. Instrument cohorts like a SaaS company

CAC by channel, day-one recovery, monthly cohort revenue curves, payback, and margin-adjusted LTV, reported consistently over enough quarters to show stability. General Catalyst underwrote IM8's consistency across geographies, tenors, and products, not just its averages. Noisy cohort curves can't be financed, no matter how good the averages look.

2. Engineer subscription attach at the point of sale

IM8's roughly 80% attach rate didn't happen after checkout, it happened at checkout: subscription-default purchase flow, meaningful subscribe-and-save economics, and a product with a natural depletion cycle. This is the number to move first, because every other metric in the model compounds off it.

3. Pull cash forward with billing structure

The quarterly-plan migration is the most copyable single tactic in this story. Longer billing periods shorten payback mechanically, cut shipping cost per revenue dollar, and reduce churn events from twelve decisions a year to four. Test quarterly or annual plans with a real incentive. Even 30 to 50% adoption transforms cash conversion.

4. Premiumize, don't discount

Growth bought with discounts destroys the margin assumption any financier will price against, and it usually shows up first in contribution margin. If you haven't run the math in the three-layer contribution margin read, start there. Bundles, premium SKUs, and plan upgrades raise AOV without eroding the margin line.

5. Know the financing ladder

CVF-scale capital requires IM8-grade data, but the category exists at every size, on progressively worse terms as you go down-market. The discipline that eventually gets you cheap money also makes the earlier, expensive money safer to use. The qualifying question at every rung is the one General Catalyst's Pranav Singhvi poses: not "how much marketing can we afford?" but "what is the provable return on our acquisition spend?" (CVF Fund, Marketing as the New CapEx). For who's writing checks into consumer right now, see the funding rounds tracker.

6. Set the guardrails before the money arrives

The bear case above is instructive even if you never raise a dollar of this. Set marginal-CAC ceilings per channel and day-one recovery floors before deploying outside capital, because the model breaks quietly at the margins first. Start with your max allowable CAC and hold the line on it when the spending gets easy.

One line to remember: the celebrity got IM8 attention, the cohort data got it the billion. Engineer subscription-grade economics into the product, prove cohort consistency with clean first-party data, then convert that proof into cheaper capital. That sequence works at $2 million just as well as at $200 million. The wellness M&A market is already paying premiums for exactly this profile, as I covered in who's buying supplement brands in 2026.

Questions worth
answering straight.

How fast did IM8 grow?

What did General Catalyst actually underwrite?

Is the IM8 deal equity?

What is the biggest risk in the IM8 deal?

What can a smaller brand copy from IM8?

Watch what IM8 does next, not what it says. The margin trajectory as hydration and gummies launch, the retention curves as the earliest cohorts hit month 24, and whether the acquisition engine holds up under 10x the spend. Those three data points will tell you whether this was the deal that proved marketing is capex for consumer brands, or the one that showed why it isn't.